Product Comparison


 
Glaxo Specialty 00173089242
Glaxo Specialty 00173088101
Glaxo Specialty 00173090442
Glaxo Specialty 00173089201
McKesson # 1184538 1184533 1211887 1184535
Description NUCALA® Mepolizumab 100 mg / mL Injection Prefilled Syringe NUCALA® Mepolizumab Injection Single-Dose Vial NUCALA® Mepolizumab 40 mg Injection Prefilled Syringe 0.4 mL NUCALA® Mepolizumab Injection Prefilled Auto-Injector
Manufacturer # 00173089242001730881010017309044200173089201
Brand NUCALA®NUCALA®NUCALA®NUCALA®
Manufacturer Glaxo SpecialtyGlaxo SpecialtyGlaxo SpecialtyGlaxo Specialty
Invoice NUCALA, PFS 100MG/MLNUCALA, SDV 100MGNUCALA, PFS 40MG/0.4MLNUCALA, PF AUTOINJECT 100MG/ML
    Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison
Container Type Prefilled SyringeSingle-Dose VialPrefilled SyringePrefilled Auto-Injector
NDC Number 00173089242001730881010017309044200173-0892-01
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 days
Strength 100 mg / mL40 mg
UNSPSC Code 51202400512024005116220051202400
Volume 0.4 mL
Application Interleukin-5 (IL-5)Interleukin-5 (IL-5)Interleukin-5 (IL-5)Interleukin-5 (IL-5)
Country of Origin UnknownUnknownUnknownUnknown
Dosage Form InjectionInjectionInjectionInjection
Generic Drug Name MepolizumabMepolizumabMepolizumabMepolizumab
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type SubcutaneousSubcutaneousSubcutaneousSubcutaneous
Features and Benefits
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non hematologic secondary cause.
  • Requires Refrigeration
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non hematologic secondary cause.
  • Requires Refrigeration
  • Prior to Dispensing: Refrigerate prefilled autoinjectors and prefilled syringes at 36°F to 46°F (2°C to 8°C),
  • Keep the product in the original carton to protect from light
  • Do not freeze
  • Do not shake
  • Avoid exposure to heat
  • 40 mg/0.4 mL, single-dose, prefilled glass syringe with attached 29-gauge, half-inch needle with a needle guard in cartons of 1 (NDC 0173-0904-42)
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non hematologic secondary cause.
  • Requires Refrigeration